Dexcom ( NASDAQ:DXCM ) stock ended Friday's trading session on a rough slate despite the company's first-quarter beat and boosted sales guidance. Sales guidance, however, was light at the midpoint and Dexcom ( NASDAQ:DXCM ) stock plummeted 10%, closing at 124.34. easily boycotting a recent buy point at 132.03 out of a flat base. Some analysts noted that the...
Analyzing the options chain and the chart patterns of DXCM DexCom prior to the earnings report this week, I would consider purchasing the 137usd strike price Calls with an expiration date of 2024-5-3, for a premium of approximately $5.95. If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
GEHC is a new spinoff from General Electric. It has great success thus far with good earnings reports and no dependency on debt and interest rates. It has been on an uptrend since the November earnings. At present it is correcting. I will play this going short on shares while hedging with a long term call options. I am in GE calls out into 2026. A long term...
IRTC on the weekly chart shows a symmetrical triangle with compression of price into the apex confluent with the 5 year anchored mean VWAP. I am very familiar with the product line including often lifesaving technology such as AEDs. The company has had weak earnings reports but price has managed to so from undervalued to fair value. I will add to my...
ZBH is a big global medical device company. It is old school. Aluminum titanium polymers, plates screws wires. Hollywood stars are familiar as it makes the devices for leg lengthening surgery. ( shortening is easy, lengthening not so much) I am familiar because in the past I have served as a consultant for this company. It business is mainly orthopedic elective...
DexCom, Inc. DXCM reported third-quarter 2023 adjusted earnings per share (EPS) of 50 cents, which beat the Zacks Consensus Estimate of 22 cents by 47.1%. The company reported earnings of 28 cents per share in the prior-year quarter. DXCM registered GAAP net income per share of 29 cents, up from the year-ago quarter’s figure of 24 cents. Shares of DexCom rose...
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? DexCom (DXCM), which belongs to the Zacks Medical - Instruments industry, could be a great candidate to consider. This medical device company has an established record of topping earnings estimates,...
Company: Dexcom Inc. Ticker: DXCM Exchange: NASDAQ Sector: Health Technology Introduction: Our technical analysis today concentrates on Dexcom Inc. (DXCM), a prominent name in the Health Technology sector, listed on the NASDAQ. A potential Cup and Handle pattern, serving as a reversal formation, has been forming on the weekly chart, suggesting a promising...
DexCom - 30d expiry - We look to Sell a break of 108.48 (stop at 113.03) We are trading at overbought extremes. Although the bulls are in control, the stalling positive momentum indicates a turnaround is possible. A break of the recent low at 108.68 should result in a further move lower. This stock has seen poor sales growth. Levels above 122 continue to...
NASDAQ:PODD & NASDAQ:DXCM are leading the sectors recovery. Both are in the Medical Products Industry for diabetes. Insulent (PODD) normally outperforms DexCom (DXCM) during and after a correction. Then, when they are in sustained uptrends, DXCM outperforms. For the recent correction, PODD has a -45% deep base while DXCM has a -58%. PODD bottmed 4 weeks...
I'm a bit surprised this isn't getting more attention here. Breakout failed about the channel on a few price upgrades.--> That shouldn't be enough to hold a rally and is proving itself out. Short position entered at 102, PT on this would be 95 on volume profile, then 85 based on gap fill if it picks up steam.
Everything is red, especially after last weeks volatility. This stock here seems to be a tech company primarily focused on medical technology seemingly with target for our geriatric community here in the US. I haven't done much research but from a chart analysis I see the potentiality for this stock to play out strong in the future.
DexCom Short Term - We look to Buy at 74.01 (stop at 60.52) A bullish reverse Head and Shoulders is forming. This is positive for sentiment and the uptrend has potential to return. There is scope for mild selling at the open but losses should be limited. Support is located at 70.00 and should stem dips to this area. Dip buying offers good risk/reward. Our...
Consolidation is broken upwards with the minimum target level around 605.
DXCM all map on the chart make sure your stop loses is more than H area by 10 USD . thanks
Waiting for price to break out of the pennant here. The targets are provided based on Fibs.
broke all the way through the cloud and got all the signals aligned, looks good for liftoff